Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC)

PHASE4CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Pulmonary EmbolismPulmonary Thromboembolism
Interventions
DRUG

Recombinant Streptokinase

Recombinant streptokinase: 1.5 million IU continuously intravenous infusion for 2 hours

DRUG

Urokinase

Urokinase: 20,000 IU/kg continuously intravenous infusion for 2 hours

Trial Locations (8)

100020

Beijing Institute of Respiratory Medicine, Beijing Chao-Yang hospital, Beijing

110016

The General Hospital of Shenyang Military Command, Shenyang

266003

The Affiliated Hospital of Medical College Qingdao University, Qingdao

300052

Tianjin Medical University General Hospital, Tianjin

510120

Guangdong Institute of Respiratory Disease, Guangzhou Medical University,, Guangzhou

518020

Shenzhen People's Hospital, Shenzhen

750004

Affiliated Hospital of Ningxia Medical University, Yinchuan

030001

The First Affiliated Hospital of Shanxi Medical University, Taiyuan

Sponsors
All Listed Sponsors
collaborator

Qingdao University

OTHER

collaborator

Tianjin Medical University General Hospital

OTHER

collaborator

General Hospital of Shenyang Military Region

OTHER

collaborator

Guangdong Institute of Respiratory Disease

UNKNOWN

collaborator

The First Affiliated Hospital of Shanxi Medical University

OTHER

collaborator

Shenzhen People's Hospital

OTHER

collaborator

Ningxia Medical University

OTHER

lead

Beijing Chao Yang Hospital

OTHER